Notícias e Atividades da Supernus Pharmaceuticals

Supernus Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Supernus Pharmaceuticals é uma empresa listada sob o símbolo SUPN (US).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Supernus Pharmaceuticals

• Jack Khattar, President, Chief Executive Officer and Director
• Carrolee Barlow, Director
• John Siebert, Director

Criar um alerta
para seguir os movimentos de executivos da Supernus Pharmaceuticals.

Supernus Pharmaceuticals possui 1.832 concorrentes concorrentes Pfizer (Estados Unidos), Eli Lilly (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).
• Jazz Pharmaceuticals adquiriu Chimerix (publicado em 6 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica >

Últimos comunicados de imprensa de Supernus Pharmaceuticals

• Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 | Supernus Pharmaceuticals
• Supernus to Participate in the Jefferies Healthcare Conference | Supernus Pharmaceuticals
• Supernus Announces First Quarter 2022 Financial Results | Supernus Pharmaceuticals
• Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022 | Supernus Pharmaceuticals
• Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults | Supernus Pharmaceuticals
• Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer - Supernus Pharmaceuticals
• Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments - Supernus Pharmaceuticals
• Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference - Supernus Pharmaceuticals
• Supernus to Present at the Wells Fargo Virtual Health Care Conference - Supernus Pharmaceuticals
• Supernus Announces Second Quarter 2020 Financial Results - Supernus Pharmaceuticals
• View more press releases Close

Redes sociais sobre Supernus Pharmaceuticals

• Supernus Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Supernus Pharmaceuticals na LinkedIn, Twitter e YouTube